An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis Pharmaceuticals1 site in 1 country11 target enrollmentMay 2006

Overview

Phase: Phase 2
Intervention: imatinib mesylate
Conditions: Malignant Peripheral Nerve Sheath Tumors
Sponsor: Novartis Pharmaceuticals
Enrollment: 11
Locations: 1
Primary Endpoint: Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.
Status: Terminated
Last Updated: 13 years ago

This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors

Registry

clinicaltrials.gov

Start Date

May 2006

End Date

April 2009

Last Updated

13 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Sponsor

Responsible Party

Sponsor

Intervention: imatinib mesylate

Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.

Time Frame: Every 36 weeks

Time to progression assessed by an MRI scan.(Every 36 weeks)
Overall survival(Every 36 weeks)
Safety and tolerability assessed by abnormal lab values (hematology, biochemistry, urinalysis), by physical examination and vital signs(Every 36 weeks)